Company code: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) company abbreviation: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332)
Summary of annual report 2021
1、 Important tips
1.1 the summary of the company’s annual report is extracted from the full text of the company’s annual report for 2021 as of December 31, 2021. In order to fully understand the company’s operating results, financial status and future development plan, investors should carefully read it and publish it on the website of Shanghai Stock Exchange（ http://www.sse.com.cn. ）HKEx website（ http://www.hkex.com..hk ）And the full text of the annual report on the website.
1.2 the board of directors, the board of supervisors and the directors, supervisors and senior managers of the company guarantee the authenticity, accuracy and completeness of the abstract, and there are no false records, misleading statements or major omissions, and bear individual and joint legal liabilities.
1.3 all directors of the company attended the 19th meeting of the 8th board of directors, among which Mr. Huang Xianrong, an independent non-executive director, attended the meeting by means of communication.
1.4 the financial reports of the group and the company for the reporting period were prepared in accordance with the Chinese accounting standards for business enterprises, audited by Lixin Certified Public Accountants (special general partnership) and issued a standard unqualified audit report.
1.5 the profit distribution plan or the plan of converting accumulation fund into share capital in the reporting period approved by the resolution of the board of directors
The audit of Lixin Certified Public Accountants (special general partnership) confirmed that in 2021, the group realized the consolidated net profit attributable to the shareholders of the company of RMB 371987768046. Based on the company’s net profit of RMB 188410981135 in 2021, 10% statutory surplus reserve of RMB 18841098114 was withdrawn, plus the undistributed profit carried forward at the beginning of last year of RMB 67785 Cecep Wind-Power Corporation(601016) 2, After deducting the cash dividend of RMB 87467553056 in 2020, the profit available for distribution at the end of the period is RMB 759958340127.
According to the actual situation of the company, based on the total share capital of 1625790949 shares at the end of 2021, it is proposed to distribute cash dividends of RMB 6.87 (including tax) for every 10 shares, with a total cash dividend of RMB 111691838196, accounting for 30.03% of the net profit attributable to the shareholders of the company in the consolidated income statement of the current year and 33.78% of the net profit excluding non recurring profits and losses attributable to the shareholders of the company in the current year. The remaining unallocated will be transferred to the next distribution. No capital reserve will be converted into share capital in this year.
The profit distribution plan is proposed to be submitted to the 2021 annual general meeting of the company for deliberation and approval.
1.6 this abstract is prepared in Chinese and English respectively. In case of any ambiguity in interpretation between the two versions, the Chinese version shall prevail.
1.7 in accordance with paragraph 45 of Appendix 16 to the Listing Rules of the Hong Kong stock exchange, all information required to be contained in this abstract will be published on the website of the Hong Kong stock exchange.
2、 Interpretation
In this abstract, unless the context otherwise requires, the following words have the following meanings:
Company / the company / Guangzhou Pharmaceutical Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) refers to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332)
China means the people’s Republic of China
The reporting period / year / year refers to the period from January 1, 2021 to December 31, 2021
The group refers to the company and its subsidiaries
Board of directors means the board of directors of the company
Director means a director of the company
Board of supervisors refers to the board of supervisors of the company
Supervisor refers to the supervisor of the company
Shanghai stock exchange refers to Shanghai Stock Exchange
HKEx means the stock exchange of Hong Kong Limited
Articles of association means the articles of association of the company
The HKEx Listing Rules refer to the HKEx securities listing rules
Guangzhou Pharmaceutical Group refers to Guangzhou Pharmaceutical Group Co., Ltd
Zhongyi pharmaceutical refers to Guangzhou Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Zhongyi Pharmaceutical Co., Ltd
Chen Liji pharmaceutical factory refers to Guangzhou Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Chen Liji Pharmaceutical Factory Co., Ltd
Qixing pharmaceutical refers to Guangzhou Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Qixing Pharmaceutical Co., Ltd
PanGaoShou pharmaceutical refers to Guangzhou Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) PanGaoShou Pharmaceutical Co., Ltd
Jingxiutang pharmaceutical means Guangzhou Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) jingxiutang Pharmaceutical Co., Ltd
Wanglaoji pharmaceutical refers to Guangzhou Wanglaoji Pharmaceutical Co., Ltd
Wanglaojida health Co., Ltd. refers to Guangzhou wanglaojida Health Industry Co., Ltd
Guangzhou Hanfang means Guangzhou Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Hanfang Modern Pharmaceutical Co., Ltd
Pharmaceutical company refers to Guangzhou Pharmaceutical Co., Ltd. (formerly Guangzhou Pharmaceutical Co., Ltd.)
Caizhilin pharmaceutical refers to Guangzhou Caizhilin Pharmaceutical Co., Ltd
Pharmaceutical import and Export Corporation refers to Guangzhou Pharmaceutical Import and Export Co., Ltd
Guangyao Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Hong Kong company refers to Guangyao Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Hong Kong Company Limited
Mingxing pharmaceutical refers to Guangzhou Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Mingxing Pharmaceutical Co., Ltd
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Hehuang company refers to Guangzhou Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Hutchison Huangpu traditional Chinese Medicine Co., Ltd
Wanglaojiya’an company refers to wanglaojida health industry (Ya’an) Co., Ltd
Chemical Medicine Technology Co., Ltd. refers to Guangzhou Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Chemical Medicine Technology Co., Ltd
Chemical Pharmaceutical (Zhuhai) company refers to Guangyao Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Chemical Pharmaceutical (Zhuhai) Co., Ltd
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Yihu company refers to Guangzhou Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Yihu Health Technology Co., Ltd
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) health care company refers to Guangzhou Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) health care medical supplies Co., Ltd
Guangzhou Pharmaceutical General Hospital refers to Guangzhou Pharmaceutical Research Institute Co., Ltd
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) medical and health industry company refers to Guangzhou Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) medical and Health Industry Investment Co., Ltd
Medical device investment company refers to Guangzhou Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) medical device investment Co., Ltd
Guangzhou Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) hospital refers to Guangzhou Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) hospital Co., Ltd
Runkangyue subsidiary refers to Guangzhou Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) runkangyue Club Co., Ltd
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Yixintang Pharmaceutical Group Co.Ltd(002727) refers to Guangzhou Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Yixintang Pharmaceutical Group Co.Ltd(002727) pharmaceutical investment development Co., Ltd
The abbreviation of good manufacturing practice in English refers to a set of mandatory standards applicable to the pharmaceutical industry, which requires enterprises to ensure that the drug quality meets the national standards in accordance with the requirements of GMP in the process of drug production
The abbreviation of direct to pharmacy refers to the English abbreviation of direct to patient service provided by pharmacy
The national catalogue of essential drugs (2018 Edition), the national catalogue of essential drugs, is the basis for the allocation and use of drugs in medical institutions.
The national catalogue of basic drugs refers to the drugs in the catalogue of essential drugs that meet the basic medical and health needs, have appropriate dosage forms, are reasonable in price, can ensure supply and are fairly available to the public
The national medical insurance catalogue of drugs for national basic medical insurance, industrial injury insurance and maternity insurance refers to the catalogue (2020 Edition), which is the standard for the payment of drug expenses by the funds for basic medical insurance, industrial injury insurance and maternity insurance
The provincial medical insurance catalogue refers to the provincial catalogue of drugs for basic medical insurance, industrial injury insurance and maternity insurance issued by all provinces
DRGs payment refers to the payment by grouping related to disease diagnosis
Guangzhou Guofa index Guangzhou state owned Assets Development Holding Co., Ltd
Guangzhou Chengfa refers to Guangzhou Guoshou urban development industry investment enterprise (limited partnership)
3、 Basic information of the company
3.1 company profile
Stock abbreviation Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332)
Stock abbreviation before change Guangzhou Pharmaceutical
Stock Code: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) (A shares)
Listed Stock Exchange Shanghai Stock Exchange
Stock abbreviation Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332)
Stock Code: 0874 (H shares)
Listed stock exchange: stock exchange of Hong Kong Limited
Contact person and contact information secretary of the board of directors securities affairs representative
Name: Huang Xuezhen, Huang Ruimei
Contact address: No. 45, Shamian North Street, Liwan District, Guangzhou, Guangdong, China
Tel: (8620) 66281218 (8620) 66281216
Fax (8620) 66281229
E-mail [email protected]. [email protected].
3.2 introduction to the company’s main business in the reporting period
Since its establishment, the company has been focusing on the pharmaceutical and health industry. After years of development, the scale and benefits continue to expand. At present, the group is mainly engaged in: (1) research, development, manufacturing and sales of Chinese and Western patent medicine, chemical API, natural medicine, biomedicine and chemical API intermediates; (2) Wholesale, retail, import and export of Western medicine, traditional Chinese medicine and medical devices; (3) R & D, production and sales of big health products; And (4) investment in health industries such as medical services, health management, health care and elderly care.
3.2.1 Great Southern pharmaceutical sector (pharmaceutical manufacturing business)
The company has 27 pharmaceutical manufacturing enterprises and institutions (including 3 branches, 21 holding subsidiaries and 3 joint ventures) engaged in the R & D, manufacturing and sales of Chinese and Western patent medicines, chemical API, chemical API intermediates, biomedicine and natural drugs.
(1) The group is a master of Nanpai traditional Chinese medicine. The company has 12 Chinese time-honored pharmaceutical enterprises, including Zhongyi pharmaceutical, Chen Liji pharmaceutical, Qixing pharmaceutical, jingxiutang pharmaceutical and pan Gaoshou pharmaceutical, of which 10 are century old enterprises. Maintain the catalogue, and 143 varieties are included in the national catalogue of basic drugs; The main traditional Chinese medicine products include Xiaoke pill, Zishen Yutai pill, Banlangen Granule Series, Xiaochaihu granule, Naoxinqing Tablet series, compound danshen tablet series, Baoji series, Huatuozaizao pill, Xiasangju granule, Zhuangyaojianshen pill, Xiaoer Qixing tea granule, Angongniuhuang pill, Shujin Jianyao pill, Qingkailing series, honey refining Chuanbei loquat ointment, etc. they have obvious brand and variety advantages of Chinese patent medicine in South China and even the whole country.
(2) The group has a complete industrial chain of antibiotics from APIs to preparations, and its product group covers common varieties of antibacterial and anti-inflammatory drugs and andrology drugs. The group integrates the brand of antibiotic drugs with the well-known trademark “kangzhiba” to build the market image of the first brand of oral antibacterial and anti-inflammatory drugs in China. The group’s chemical products include cefixime series, sildenafil citrate (trade name “Jinge”), amoxicillin, cefathiamidine, cefuroxime sodium, acaphenolate powder series, Cefpiramide, cefprozil series, etc.
3.2.2 major health sectors
The group’s big health sector is mainly engaged in the production, R & D and sales of beverages, food, health products and other products. The enterprises mainly engaged in include Wanglaoji big health company and Wanglaoji pharmaceutical, a subsidiary of the company; The main products include Wanglaoji herbal tea, ciningji series, throat candy, Guiling ointment, etc. Wang Laoji herbal tea is a
